目的 分析艾迪注射液辅助治疗肿瘤的临床应用现状，探寻艾迪注射液辅助治疗肿瘤的用药规律及疗效特征。方法 检索1989年1月—2020年12月中国期刊全文数据库（CNKI）、万方数字化期刊全文库、中文科技期刊全文数据库（维普）报道的艾迪注射液治疗肿瘤相关文献，进行资料的提取与统计分析。结果 以“益佰牌”艾迪注射液为例，共纳入文献169篇，涉及病例数14 050例，多为100人以下的小规模研究，报道的肿瘤类型以肺癌最多，多以有效率提高、KPS评分改善、不良反应发生率减少、临床症状改善、免疫功能增强、一年生存率提高及CEA、AFP等生化指标改善作为临床疗效的评价指标。结论 基于回顾性文献分析发现艾迪注射液临床应用广泛，疗效确切，在减少化疗副作用基础上，可提高患者的生活质量，但文献质量不是很高，作为证据级别尚显不够，值得临床进一步深入研究。

Objective To analyze the current status of the clinical application of Aidi Injection in adjuvant treatment of tumors, and explore the drug administration rules and efficacy characteristics of Aidi Injection in the treatment of tumors. Methods China Journal Full-text Database (CNKI), Wanfang Database, Chinese Science and Technology Journal Full-text Database (VIP) were retrieved from January 1989 to December 2020, and the literature involving cases were extracted and analyzed. Results Taking “Yibai” Aidi Injection as an example, a total of 169 articles were included, involving a small-scale study of 14 050 cases and mostly less than 100 people. The most reported types of tumor were lung cancer. Improved efficiency, KPS score improvement, reduction of incidence of adverse reactions, improvement of clinical symptoms, enhancement of immune function, improvement of one-year survival rate, and improvement of physical and chemical indicators such as CEA and AFP were used as evaluation indicators of clinical efficacy. Conclusion Based on literature analysis, it is found that Aidi Injection has a wide range of clinical application and exact effect. It can improve the quality of life of patients on the basis of reducing the side effects of chemotherapy, but the quality of the literature is not very high, and the level of evidence is not enough. It is worth further clinical research.

R979.1